middle.news
Orthocell Surges with Record H1 Revenue and Rapid US Expansion
9:12am on Tuesday 24th of February, 2026 AEDT
•
Healthcare
Read Story
Orthocell Surges with Record H1 Revenue and Rapid US Expansion
9:12am on Tuesday 24th of February, 2026 AEDT
Key Points
Record H1 FY26 revenue up 48% to $6.2 million
Remplir™ approved in 45 US states with growing hospital accounts
Exclusive Canadian distribution secured, first sales expected H1 CY26
EU and UK regulatory submission underway, approval targeted Q3 CY26
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ORTHOCELL (ASX:OCC)
OPEN ARTICLE